FEMASYS INC (FEMY) awards 6,250 stock options to Chief Clinical-Medical Affairs

Rhea-AI Filing Summary

FEMASYS INC reported that executive Jeffrey Gerald Mifek, Chief Clinical-Medical Affairs, received a grant of stock options covering 6,250 shares of common stock. The options have an exercise price of $4.08 per share and expire on July 6, 2036. The underlying shares vest in equal installments over four years beginning on July 6, 2027, contingent on continued employment. Following this grant, Mifek holds options for 6,250 shares from this award.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Mifek Jeffrey Gerald

Role Chief Clinical-Medical Affairs

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy) F1	6,250	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 6,250 shares (Direct)

Footnotes (1)

1. F1. The shares underlying the stock option vest equally in installments over 4 years beginning on July 6, 2027, provided that the reporting person is employed by the Issuer or a subsidiary of the Issuer on the vesting date.

Key Figures

Options granted: 6,250 shares Exercise price: $4.08 per share Expiration date: July 6, 2036 +2 more

5 metrics

Options granted 6,250 shares Stock Option (Right to Buy) granted to Jeffrey Gerald Mifek on July 6, 2026

Exercise price $4.08 per share Conversion or exercise price of the stock options

Expiration date July 6, 2036 Option expiration for the 6,250-share grant

Vesting start date July 6, 2027 First vesting date for options, then equal installments over 4 years

Shares underlying option 6,250 shares Underlying FEMASYS INC common stock tied to this option award

Key Terms

Stock Option (Right to Buy), exercise price, vesting, underlying security

4 terms

Stock Option (Right to Buy) financial

"security_title: Stock Option (Right to Buy)"

exercise price financial

"conversion_or_exercise_price: 4.0800"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vesting financial

"shares underlying the stock option vest equally in installments over 4 years"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

underlying security financial

"underlying_security_title: Common Stock"

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 08/11/2026 - 08:51 PM Accepted by SEC EDGAR 08/11/2026 - 08:51 PM Learn about SEC filing dates

FAQ

What did FEMASYS INC (FEMY) disclose about Jeffrey Gerald Mifek in this Form 4?

FEMASYS INC disclosed that Jeffrey Gerald Mifek received a grant of stock options for 6,250 shares of common stock at an exercise price of $4.08 per share, expiring on July 6, 2036.

How many FEMASYS INC (FEMY) stock options were granted to Jeffrey Gerald Mifek and at what price?

Jeffrey Gerald Mifek was granted 6,250 stock options of FEMASYS INC common stock with an exercise price of $4.08 per share, representing a compensation-related award rather than an open-market purchase.

What is the vesting schedule of the new FEMASYS INC (FEMY) options granted to Jeffrey Gerald Mifek?

The options granted to Jeffrey Gerald Mifek vest equally over four years, starting on July 6, 2027, provided he remains employed by FEMASYS INC or one of its subsidiaries on each vesting date.

When do Jeffrey Gerald Mifek’s FEMASYS INC (FEMY) stock options expire?

The stock options granted to Jeffrey Gerald Mifek expire on July 6, 2036. This gives a 10-year term from the grant date for potential exercise, subject to vesting and continued employment conditions.

How many FEMASYS INC (FEMY) derivative securities does Jeffrey Gerald Mifek hold after this Form 4 transaction?

After this transaction, Jeffrey Gerald Mifek holds 6,250 stock options from this grant. These options relate to 6,250 underlying common shares and are held as direct ownership according to the filing.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Mifek Jeffrey Gerald

(Last) (First) (Middle)

C/O FEMASYS INC.

3950 JOHNS CREEK COURT, SUITE 100

(Street)

SUWANEE GEORGIA 30024

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
FEMASYS INC [ FEMY ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Clinical-Medical Affairs

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/06/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$4.08	07/06/2026		A		6,250		(1)	07/06/2036	Common Stock	6,250	$0	6,250	D

Explanation of Responses:

1. The shares underlying the stock option vest equally in installments over 4 years beginning on July 6, 2027, provided that the reporting person is employed by the Issuer or a subsidiary of the Issuer on the vesting date.

	/s/ Kathy Lee-Sepsick, Attorney-in-fact	08/11/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)